Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
waveLINE-006: MK-2140 in Relapsed or Refractory B-cell Malignancies
jRCT2011230019Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of zilovertamab vedotin in malignant B-cell neoplasm, mantle cell lymphoma (MCL), Richter's syndrome (RS) and 2 more (2 arms), sponsored by Merck & Co. Primary endpoint: Safety and tolerability. Started Sep 2023; status: active, not recruiting.
02
Drugs
zilovertamab vedotin
03
Conditions
malignant B-cell neoplasmmantle cell lymphoma (MCL)Richter's syndrome (RS)follicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT2011230019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230019.